A cluster of human T-lymphotropic virus type-I carriers found in the southern district of Tokushima Prefecture. NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


A cluster of human T-lymphotropic virus type-I carriers found in the southern district of Tokushima Prefecture.

Jpn J Clin Oncol. 1989 Mar;19(1):30-5. Unique Identifier : AIDSLINE MED/89157716
Kosaka M; Iishi Y; Horiuchi N; Nakao K; Okagawa K; Saito S; Minami Y; Katoh K; First Department of Internal Medicine, School of Medicine,; University of Tokushima.


Abstract: Since we had experience of eight patients with adult T-cell leukemia lymphoma from 130 cases of non-Hodgkin's lymphoma between 1978 and 1986, a sero-epidemiological survey of anti human lymphotropic virus type-I (HTLV-I) antibody was performed using a gelatin particle agglutination test, an enzyme-linked immunosorbent assay and an indirect immunofluorescence assay for 2,190 adults (768 men and 1,422 women) aged between 21 and 86 years, in the southern district of Tokushima Prefecture. The inconclusive data obtained using the above mentioned methods have been re-examined by western blotting analysis using enzyme-labelled anti IgM and anti IgG. There was an overall prevalence rate of 6.0% (132/2, 190) but higher rate were found in village C (10.9%) and village D (14.2%). These two villages together with town K (6.1% seropositive) form one community unit with a small population in a mountain area, which could be prone to producing a cluster of HTLV-I carriers. Town G with 8.0% sero-positivity is on the Pacific Ocean coast neighboring one of the endemic areas in the eastern section of Kohchi Prefecture. Interestingly, only IgM antibody was detected in 17 of 137 carriers (13%), all females who had never had a blood transfusion, suggesting them to h ave been in a sort of immunodeficient state, as reported in cases of HTLV-I infection. In 13 of 29 HTLV-I carriers (44.8%) from villages C and D, the viral antigen was detected in 1-9% (0.41 +/- 0.19%) of the peripheral blood mononuclear cells after being cultured with phytohemagglutinin for three days. The data indicate that those carriers had evidently been infected with the HTLV-I virus.
Keywords: Adult Aged Aged, 80 and over Agglutination Tests Blotting, Western Carrier State/*EPIDEMIOLOGY Cross-Sectional Studies Enzyme-Linked Immunosorbent Assay Female Fluorescent Antibody Technique Human HTLV-I Antibodies/*ANALYSIS HTLV-I Antigens/ANALYSIS IgG/ANALYSIS IgM/ANALYSIS Japan Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/*EPIDEMIOLOGY/ IMMUNOLOGY Male Middle Age JOURNAL ARTICLE

KWDadultagedaged,80andoveragglutinationtestsblotting,westerncarrierstate/KWDepidemiologycross-sectionalstudiesenzyme-linkedimmunosorbentassayfemalefluorescentantibodytechniquehumanhtlv-iantibodies/KWDanalysishtlv-iantigens/analysisigg/analysisigm/analysisjapanleukemia-lymphoma,t-cell,acute,htlv-i-associated/KWDepidemiology/immunologymalemiddleagejournalarticle
890630
M8960125


Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .